EUVIMEDEUVIMED entdecken
Crossref

Update on Rivaroxaban

Osama Moussa, Dipankar Chattopadhyay, Vish Bhattacharya

Clinical medicine. Blood disorders · 2010

DOI: 10.4137/cmbd.s5101 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical medicine. Blood disorders, 2010. Verfasst von Osama Moussa und 2 weiteren Autor:innen. Die Arbeit nennt 47 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anticoagulants are recommended for the prevention and treatment of venous thromboembolism (VTE). The new anticoagulants which target specific factors in the coagulation cascade offer the advantage that they can be administered orally. These drugs seek to offer safe anticoagulation without the need for regular monitoring and frequent dose adjustment. Some of these newer drugs are in the advanced stages of clinical trials or have already completed them and thereby aim to provide more options in the management of thromboembolism. In the present review we discuss the currently available evidence supporting the use of these new anticoagulants, in particular rivaroxaban.

Zitieren

APA

Moussa, O., Chattopadhyay, D., & Bhattacharya, V. (2010). Update on Rivaroxaban. Clinical medicine. Blood disorders. https://doi.org/10.4137/cmbd.s5101

Vancouver

Moussa O, Chattopadhyay D, Bhattacharya V. Update on Rivaroxaban. Clinical medicine. Blood disorders. 2010. doi:10.4137/cmbd.s5101

BibTeX
@article{Moussa2010,
  author = {Moussa, Osama and Chattopadhyay, Dipankar and Bhattacharya, Vish},
  title = {Update on Rivaroxaban},
  journal = {Clinical medicine. Blood disorders},
  year = {2010},
  doi = {10.4137/cmbd.s5101}
}
Kostenlos starten →